Astellas Pharma Inc: Diabetes Mellitus, Type 2 trials

The registry lists 35 Diabetes Mellitus, Type 2 studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 6Phase 2 8Phase 3 15Phase 4 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Compare the Use of Diabetes Treatment Support System (BAP0527 and Blood Glucose Meter) in Addition to Daily Practice and Treatment With Daily Practice and Treatment Alone in Patients With Type 2 Diabetes MellitusCompletedNCT06156696Results posted
• A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With AlbuminuriaTerminatedNCT03118713Phase 4
• Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin TherapyCompletedNCT02847091Phase 4
• A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on MetforminCompletedNCT02794792Phase 3
• Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus PatientsTerminatedNCT02786979Phase 4
• Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes PatientsCompletedNCT02479399
• A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinCompletedNCT02452632Phase 3
• A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT02358096Phase 2
• The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes PatientsCompletedNCT02297620
• Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02291874Phase 4
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney DiseaseCompletedNCT02218099Phase 1/2
• A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes MellitusCompletedNCT02175784Phase 4
• A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes PatientsCompletedNCT01672762Phase 3
• A Phase 1 Study to Investigate the Mechanism of Action of IpragliflozinCompletedNCT01611363Phase 1
• A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusTerminatedNCT01514838Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes PatientsCompletedNCT01505426Phase 3
• A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsCompletedNCT01316107Phase 3
• A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal ImpairmentCompletedNCT01316094Phase 3
• Drug to Drug Interaction Study With ASP1941 and MetforminCompletedNCT01302145Phase 1
• Renal Impairment Study With ASP1941CompletedNCT01302028Phase 1
• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsCompletedNCT01242228Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic PatientsCompletedNCT01242215Phase 3
• A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsCompletedNCT01242202Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsCompletedNCT01225081Phase 3
• A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic PatientsCompletedNCT01135433Phase 3
• A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes MellitusCompletedNCT01117584Phase 2
• A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal ImpairmentCompletedNCT01097681Phase 1
• A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes MellitusCompletedNCT01071850Phase 2
• A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes PatientsCompletedNCT01057628Phase 3
• A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic PatientsCompletedNCT01054092Phase 3
• A Study of ASP1941 in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01023945Phase 1
• A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.CompletedNCT00790660Phase 2
• A Study of ASP1941 in Participants With Type 2 Diabetes MellitusCompletedNCT00621868Phase 2
• A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus SubjectsCompletedNCT00454233Phase 2
• Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic PatientsCompletedNCT00189774Phase 2/3